Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17743
Country/Region: Nigeria
Year: 2014
Main Partner: Pro-Health International
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: HHS/CDC
Total Funding: $3,716,158 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Pro-Health International (PHI) through strategic partnerships with the government of Nigeria (GON), civil service organizations, private and community structures will support the implementation of an efficient national HIV response. Through the Integrated Program for Sustainable Action against HIV/AIDS in Nigeria (IPSAN) PHI shall build capacity of GON, service delivery facilities (SDF) and community based organizations (CBO) to manage high quality cost effective and sustainable HIV/AIDS prevention care and treatment programs in selected local government areas (LGA) of FCT, Nasarawa and Plateau states.

IPSAN goal is to reduce HIV morbidity and mortality in Nigeria and program strategic objectives include preventing new infections in target populations (SO1), provision of high quality care and treatment services in target communities (SO2), and strengthening the GON to effectively manage a sustainable HIV response.

PHI plans to increase access and coverage of HIV services for PLHIV in supported LGAs within FCT and Nasarawa states with an emphasis on targeted expansion of PMTCT service coverage and increased access to HIV treatment through PITC at SDFs and robust community based HTC with strong referral-linkage systems to care. PHI will provide lab platforms for HIV (including EID) diagnosis, monitoring of disease progression and ARV side effects.

PHI shall expand access to care at primary health care level using the hub and spoke decentralization model while ensuring that entire health systems are strengthened through service integration and collaboration with existing programs. Services shall be rendered using culturally and gender sensitive strategies and innovations with a robust HMIS to facilitate evidence based programming.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $525,367
Care: Orphans and Vulnerable Children (HKID) $158,456
Care: TB/HIV (HVTB) $246,911
Care: Pediatric Care and Support (PDCS) $35,692
Laboratory Infrastructure (HLAB) $241,296
Biomedical Prevention: Injection Safety (HMIN) $20,000
Testing: HIV Testing and Counseling (HVCT) $357,333
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $499,971
Treatment: Adult Treatment (HTXS) $1,525,227
Treatment: Pediatric Treatment (PDTX) $105,905
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age: 0-9 2015 4
GEND_GBV Age: 10-14 2015 9
GEND_GBV Age: 15-17 2015 13
GEND_GBV Age: 18-24 2015 7
GEND_GBV Age: 25+ 2015 4
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 29
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 8
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 29
GEND_GBV Number of people receiving post-GBV care 2015 37
GEND_GBV Sex: Female 2015 25
GEND_GBV Sex: Male 2015 12
GEND_GBV Sum of Age disaggregates 2015 37
GEND_GBV Sum of Sex disaggregates 2015 37
HTS_TST Age/sex: <1 Female 2015 814
HTS_TST Age/sex: <1 Female 2015 814
HTS_TST Age/sex: <1 Male 2015 782
HTS_TST Age/sex: <1 Male 2015 782
HTS_TST Age/sex: 1-4 Female 2015 669
HTS_TST Age/sex: 1-4 Female 2015 669
HTS_TST Age/sex: 1-4 Male 2015 639
HTS_TST Age/sex: 1-4 Male 2015 639
HTS_TST Age/sex: 10-14 Female 2015 593
HTS_TST Age/sex: 10-14 Female 2015 593
HTS_TST Age/sex: 10-14 Male 2015 578
HTS_TST Age/sex: 10-14 Male 2015 578
HTS_TST Age/sex: 15-19 Female 2015 10,227
HTS_TST Age/sex: 15-19 Female 2015 10,227
HTS_TST Age/sex: 15-19 Male 2015 6,409
HTS_TST Age/sex: 15-19 Male 2015 6,409
HTS_TST Age/sex: 20-24 Female 2015 26,240
HTS_TST Age/sex: 20-24 Female 2015 26,240
HTS_TST Age/sex: 20-24 Male 2015 13,266
HTS_TST Age/sex: 20-24 Male 2015 13,266
HTS_TST Age/sex: 25-49 Female 2015 62,903
HTS_TST Age/sex: 25-49 Female 2015 62,903
HTS_TST Age/sex: 25-49 Male 2015 41,675
HTS_TST Age/sex: 25-49 Male 2015 41,675
HTS_TST Age/sex: 5-9 Female 2015 266
HTS_TST Age/sex: 5-9 Female 2015 266
HTS_TST Age/sex: 5-9 Male 2015 258
HTS_TST Age/sex: 5-9 Male 2015 258
HTS_TST Age/sex: 50+ Female 2015 1,330
HTS_TST Age/sex: 50+ Female 2015 1,330
HTS_TST Age/sex: 50+ Male 2015 1,292
HTS_TST Age/sex: 50+ Male 2015 1,292
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,342
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 2,256
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 100,701
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 62,642
HTS_TST Aggregated Age/sex: <15 Female 2015 2,342
HTS_TST Aggregated Age/sex: <15 Male 2015 2,257
HTS_TST Aggregated Age/sex: 15+ Female 2015 100,701
HTS_TST Aggregated Age/sex: 15+ Male 2015 62,641
HTS_TST By Test Result: Negative 2015 162,965
HTS_TST By Test Result: Negative 2015 162,964
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 167,941
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 167,941
HTS_TST Sum of Age/Sex disaggregates 2015 167,941
HTS_TST Sum of Age/Sex disaggregates 2015 167,941
HTS_TST Sum of Aggregated Age/Sex <15 2015 4,599
HTS_TST Sum of Aggregated Age/Sex <15 2015 4,598
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 163,342
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 163,343
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 167,941
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 167,941
HTS_TST Sum of Test Result disaggregates 2015 167,941
HTS_TST Sum of Test Result disaggregates 2015 167,941
HTS_TST_POS By Test Result: Positive 2015 4,976
HTS_TST_POS By Test Result: Positive 2015 4,977
OVC_ACC Age: <1 2015 98
OVC_ACC Age: 1-4 2015 410
OVC_ACC Age: 10-14 2015 394
OVC_ACC Age: 15-17 2015 229
OVC_ACC Age: 18+ 2015 49
OVC_ACC Age: 5-9 2015 459
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 1,639
OVC_ACC Sex: Female 2015 836
OVC_ACC Sex: Male 2015 803
OVC_ACC Sum of Age disaggregates 2015 1,639
OVC_ACC Sum of Sex disaggregates 2015 1,639
OVC_SERV Age: <1 2015 328
OVC_SERV Age: 1-4 2015 1,366
OVC_SERV Age: 10-14 2015 1,311
OVC_SERV Age: 15-17 2015 765
OVC_SERV Age: 18+ 2015 164
OVC_SERV Age: 5-9 2015 1,530
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 5,464
OVC_SERV Sex: Female 2015 2,787
OVC_SERV Sex: Male 2015 2,677
OVC_SERV Sum of Age disaggregates 2015 5,464
OVC_SERV Sum of Sex disaggregates 2015 5,464
PMTCT_ARV Life-long ART (including Option B+) 2015 878
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 80
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 622
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,754
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,596
PMTCT_ARV Single-dose nevirapine (with or without tail) 2015 16
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 544
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 334
PMTCT_ARV Sum of New and Current disaggregates 2015 878
PMTCT_ARV Sum of Regimen Type disaggregates 2015 1,596
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 878
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 80
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 622
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,754
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,596
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 2015 16
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 544
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 334
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 878
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 1,596
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 527
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 1,069
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 80
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 1,814
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 1,596
PMTCT_EID Sum of Infant Age disaggregates 2015 1,596
PMTCT_STAT By: Known positives at entry 2015 725
PMTCT_STAT By: Number of new positives identified 2015 1,088
PMTCT_STAT Number of new ANC and L&D clients 2015 39,812
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 36,229
PMTCT_STAT Sum of Positives Status disaggregates 2015 1,813
PMTCT_STAT_NGI By: Known positives at entry 2015 725
PMTCT_STAT_NGI By: Number of new positives identified 2015 1,088
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 39,812
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 36,229
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 1,813
TB_ART Age: 0-4 2015 2
TB_ART Age: 15+ 2015 220
TB_ART Age: 5-14 2015 12
TB_ART Aggregated Age: <15 2015 14
TB_ART Aggregated Age: 15+ 2015 220
TB_ART Female 2015 119
TB_ART Known HIV-positive 2015 101
TB_ART Male 2015 115
TB_ART Newly tested 2015 133
TB_ART Sum of Aggregated Age disaggregates 2015 234
TB_ART Sum of Sex disaggregates 2015 234
TB_ART Sum of Test Status disaggregates 2015 234
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 234
TB_SCREEN Age: <1 2015 566
TB_SCREEN Age: 1-4 2015 283
TB_SCREEN Age: 10-14 2015 283
TB_SCREEN Age: 15-19 2015 2,829
TB_SCREEN Age: 20-24 2015 7,072
TB_SCREEN Age: 25-49 2015 15,558
TB_SCREEN Age: 5-9 2015 566
TB_SCREEN Age: 50+ 2015 1,132
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 1,697
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 26,592
TB_SCREEN Sex: Female 2015 19,802
TB_SCREEN Sex: Male 2015 8,487
TB_SCREEN Sum of Age disaggregates 2015 4,527
TB_SCREEN Sum of Aggregated Age disaggregates 2015 28,289
TB_SCREEN Sum of Sex disaggregates 2015 28,289
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 28,289
TX_CURR Age/Sex: <1 Female 2015 23
TX_CURR Age/Sex: <1 Male 2015 26
TX_CURR Age/Sex: 1-4 Female 2015 107
TX_CURR Age/Sex: 1-4 Male 2015 121
TX_CURR Age/Sex: 15+ Female 2015 8,219
TX_CURR Age/Sex: 15+ Male 2015 4,048
TX_CURR Age/Sex: 5-14 Female 2015 194
TX_CURR Age/Sex: 5-14 Male 2015 219
TX_CURR Aggregated Age/Sex: <1 Female 2015 23
TX_CURR Aggregated Age/Sex: <1 Male 2015 26
TX_CURR Aggregated Age/Sex: <15 Female 2015 324
TX_CURR Aggregated Age/Sex: <15 Male 2015 366
TX_CURR Aggregated Age/Sex: 15+ Female 2015 8,219
TX_CURR Aggregated Age/Sex: 15+ Male 2015 4,048
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 12,957
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 5
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 66
TX_CURR Sum of age/sex disaggregates 2015 690
TX_CURR Sum of Aggregated Age/Sex <15 2015 690
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 12,267
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 12,957
TX_CURR_NGI Age/Sex: <1 Female 2015 23
TX_CURR_NGI Age/Sex: <1 Male 2015 26
TX_CURR_NGI Age/Sex: 1-4 Female 2015 107
TX_CURR_NGI Age/Sex: 1-4 Male 2015 121
TX_CURR_NGI Age/Sex: 15+ Female 2015 8,219
TX_CURR_NGI Age/Sex: 15+ Male 2015 4,048
TX_CURR_NGI Age/Sex: 5-14 Female 2015 194
TX_CURR_NGI Age/Sex: 5-14 Male 2015 219
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 23
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 26
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 324
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 366
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 8,219
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 4,048
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 12,957
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 12,957
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 690
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 12,267
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 12,957
TX_NEW Aggregated Grouping by Age: <1 Male 2015 16
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 15
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 101
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 113
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 2,618
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 1,176
TX_NEW By Age/Sex: <1 Female 2015 15
TX_NEW By Age/Sex: <1 Male 2015 16
TX_NEW By Age/Sex: 1-4 Female 2015 20
TX_NEW By Age/Sex: 1-4 Male 2015 23
TX_NEW By Age/Sex: 10-14 Female 2015 40
TX_NEW By Age/Sex: 10-14 Male 2015 47
TX_NEW By Age/Sex: 15-19 Female 2015 393
TX_NEW By Age/Sex: 15-19 Male 2015 176
TX_NEW By Age/Sex: 20-24 Female 2015 654
TX_NEW By Age/Sex: 20-24 Male 2015 294
TX_NEW By Age/Sex: 25-49 Female 2015 1,047
TX_NEW By Age/Sex: 25-49 Male 2015 470
TX_NEW By Age/Sex: 5-9 Female 2015 25
TX_NEW By Age/Sex: 5-9 Male 2015 28
TX_NEW By Age/Sex: 50+ Female 2015 524
TX_NEW By Age/Sex: 50+ Male 2015 235
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 4,008
TX_NEW Pregnancy status 2015 209
TX_NEW Sum of Age/Sex disaggregates 2015 4,007
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 4,008
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 69
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 3,257
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 139
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 208
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 3,257
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 3,465
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 163
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 4,076
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 82
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 3,831
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 163
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 245
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 3,831
Cross Cutting Budget Categories and Known Amounts Total: $8,500
Gender: Gender Equality $8,500
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Capacity building
Equity in HIV prevention, care, treatment and support